First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer

First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer
The first patient has been dosed in a Phase 1/2 trial assessing OncoQuest's anti-CA125 antibody oregovomab in combination with Opdivo (nivolumab) in women with recurrent ovarian cancer. The ORION-01 trial (NCT03100006), which is currently enrolling participants, is being conducted at the National Cancer Centre in Singapore (NCCS). Dr. Tira Tan is leading the study, and Prof. John Chia, from Oncocare Cancer Centre, is the study's chair. "We are extremely excited about launching this study," Chia said in a press release. "Ovarian cancer is a lethal disease, and this trial may offer new hope for our patients." "Early clinical data suggests that oregovomab may improve the immune system's processing of cancer antigens, and enhance the immune ability to recognize these cancer targets," he added. "We believe that the combination of oregovomab and [Opdivo], which amplifies such immune activity, will have a synergistic effect to elicit a higher quality tumor immune response, and hence improve control of the cancer." CA125 is a glycoprotein (a protein attached to sugar molecules) expressed at the surface of ovarian cancer cells and that is also shed into circulation. OncoQuest's oregovomab targets this circulating tumor-associated antigen, inducing strong immune responses. Indeed, the CA-125 oregovomab complex is designe
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *